Dhiraj Gambhire
0000-0002-4421-5789
Publication & Citation Trends
Publications
0 total
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.
Cited by 3
Semantic Scholar
PS2-2 T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 OA
Cited by 0
Semantic Scholar
Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
Cited by 4
Semantic Scholar
Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
Cited by 14
Semantic Scholar
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Cited by 237
Semantic Scholar
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer OA
Cited by 1,669
Semantic Scholar
217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) OA
Cited by 17
Semantic Scholar
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors OA
Cited by 181
Semantic Scholar
Research Topics
HER2/EGFR in Cancer Research
(9)
Cancer Immunotherapy and Biomarkers
(6)
Advanced Breast Cancer Therapies
(6)
Breast Cancer Treatment Studies
(5)
Cancer Treatment and Pharmacology
(4)
Affiliations
Inserm
Pfizer (United States)
Université de Montpellier
Université Paris Cité
New York Oncology Hematology